[
  {
    "objectID": "notice.html",
    "href": "notice.html",
    "title": "Notice",
    "section": "",
    "text": "Welcome to the lab notice board.\nHere we will post announcements and important updates."
  },
  {
    "objectID": "notice.html#latest-announcements",
    "href": "notice.html#latest-announcements",
    "title": "Notice",
    "section": "üì¢ Latest Announcements",
    "text": "üì¢ Latest Announcements"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Hongda CHEN, Ph.D.",
    "section": "",
    "text": "Dr.¬†Hongda Chen is a Professor at Peking Union Medical College Hospital (PUMCH) of the Chinese Academy of Medical Sciences & Peking Union Medical College, and the chief of the Center for Prevention and Early Intervention of the National Infrastructure for Translational Medicine (PUMCH branch). He received his Bachelor of Preventive Medicine (2010) and Master of Epidemiology and Biostatistics (2012) from Peking University, and his PhD in Cancer Epidemiology (2016) from the German Cancer Research Center (DKFZ) and University of Heidelberg in Germany, followed by postdoctoral research at DKFZ.\nHis research centers on cancer epidemiology, with a particular focus on cancer prevention and early detection techniques/strategies. Dr.¬†Chen has published more than 80 peer-reviewed papers in leading journals such as Science Bulletin, Gut, Clinical Cancer Research, Clinical Gastroenterology and Hepatology, and American Journal of Gastroenterology, with an H-index of 37. He has led over 10 major research projects, including grants from the National Natural Science Foundation of China and national key R&D programs. In 2025, he was recognized on the World‚Äôs Top 2% Scientists List, jointly released by Stanford University and Elsevier.\nDr.¬†Chen serves on several national academic committees on cancer screening and prevention, and acts as a reviewer for top-tier journals, including the BMJ, Nature portfolio journals, JAMA series journals, and the Lancet family of journals."
  },
  {
    "objectID": "index.html#education-background",
    "href": "index.html#education-background",
    "title": "Hongda CHEN, Ph.D.",
    "section": "Education Background",
    "text": "Education Background\n\n\n\n\n\n\n\nPeriod\nInstitution & Degree\n\n\n\n\nSep.¬†2005 ‚Äì Jul.¬†2010\nPeking University, ChinaBachelor in Preventive Medicine\n\n\nSep.¬†2010 ‚Äì Jul.¬†2012\nPeking University, ChinaMaster in Epidemiology and Biostatistics\n\n\nJan.¬†2013 ‚Äì Jun.¬†2016\nUniversity of Heidelberg / German Cancer Research Center, GermanyPh.D.¬†in Epidemiology"
  },
  {
    "objectID": "index.html#working-experience",
    "href": "index.html#working-experience",
    "title": "Hongda CHEN, Ph.D.",
    "section": "Working Experience",
    "text": "Working Experience\n\n\n\n\n\n\n\nPeriod\nInstitution & Position\n\n\n\n\nFeb.¬†2016 ‚Äì Jun.¬†2016\nGerman Cancer Research Center (DKFZ)Postdoc Research Fellow\n\n\nAug.¬†2016 ‚Äì Aug.¬†2019\nNational Cancer Center, China/Cancer Hospital Chinese Academy of Medical SciencesOffice of Cancer ScreeningAssistant Professor\n\n\nSep.¬†2019 ‚Äì Feb.¬†2022\nNational Cancer Center, China/Cancer Hospital Chinese Academy of Medical SciencesOffice of Cancer ScreeningAssociate Professor\n\n\nSep.¬†2019 ‚Äì Sep.¬†2024\nPeking Union Medical College Hospital (PUMCH)Chinese Academy of Medical Sciences & Peking Union Medical CollegeCenter for Prevention and Early InterventionAssociate Professor\n\n\nSep.¬†2024 ‚Äì present\nPeking Union Medical College Hospital (PUMCH)Chinese Academy of Medical Sciences & Peking Union Medical CollegeCenter for Prevention and Early Intervention, ChiefProfessor"
  },
  {
    "objectID": "index.html#academic-societies",
    "href": "index.html#academic-societies",
    "title": "Hongda CHEN, Ph.D.",
    "section": "Academic Societies",
    "text": "Academic Societies\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSociety\nCommittee\nRole\n\n\n\n\nChinese Association for Health Promotion and Education\nCommittee of Cancer Screening and Prevention\nStanding Member / Secretary-General\n\n\nChinese Preventive Medicine Association\nEpidemiology Branch\nMember\n\n\nChinese Preventive Medicine Association\nCancer Prevention and Control Committee\nMember\n\n\nChinese Anti-Cancer Association\nCancer Epidemiology Committee\nMember"
  },
  {
    "objectID": "index.html#honors-awards",
    "href": "index.html#honors-awards",
    "title": "Hongda CHEN, Ph.D.",
    "section": "Honors & Awards",
    "text": "Honors & Awards\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nYear\nAward\nOrganization\n\n\n\n\n2025\nWorld‚Äôs Top 2% Scientists List\nStanford University and Elsevier\n\n\n2025\nOutstanding Educator\nPeking Union Medical College (PUMC)\n\n\n2024\nAdvanced Contributor to Social Practice\nPeking Union Medical College\n\n\n2024\nTop 1% Highly Cited Chinese Scholar\nChina National Knowledge Infrastructure (CNKI)\n\n\n2023\nAdvanced Contributor to Social Practice\nPeking Union Medical College (PUMC)\n\n\n2021\nUICC Technical Fellowship\nUnion for International Cancer Control (UICC)\n\n\n2019\nBeijing Science and Technology Nova\nBeijing Municipal Science & Technology Commission"
  },
  {
    "objectID": "research.html",
    "href": "research.html",
    "title": "Research Interests",
    "section": "",
    "text": "1. Cancer Epidemiology\nCancer Epidemiology and Global Burden of Disease\nCancer remains one of the leading causes of morbidity and mortality worldwide. Quantifying the epidemiology, temporal trends, and attributable risk factors of cancer is essential for guiding prevention and public health strategies. My research focuses on cancer epidemiology and global burden assessments, using population-based registries and global burden databases to characterize incidence, mortality, and preventable risk factors in China and worldwide.\n\n\n\n\n\n2. Colorectal Cancer Screening Strategies\nCohort studies, population-based programs, and RCTs.\nColorectal cancer is among the most preventable cancers through effective screening. Designing optimal strategies for large populations such as in China remains a major challenge. I conduct cohort-based studies, population-based investigations, and large-scale randomized controlled trials (RCTs) to evaluate participation, diagnostic performance, and long-term outcomes of screening methods (e.g., colonoscopy, FIT), providing evidence for population-adapted screening pathways.\n\n\n\n\n\n3. Novel Screening Technologies\nMulti-omics biomarkers and risk prediction models.\nTraditional screening tools have limitations in sensitivity, cost-effectiveness, and adaptability. My work emphasizes the development and validation of novel screening technologies, including multi-omics biomarkers (genomics, methylation, microbiome, metabolomics, proteomics) and advanced risk prediction models. I particularly focus on integrating enviromental risk scores (ERS), polygenic risk scores (PRS), metagenomics risk scores (MRS), and proteomic markers to establish precise and individualized cancer risk prediction tools.\n\n\n\n\n\n4. Health Economics & Modeling\nMicrosimulation and cost-effectiveness evaluation.\nBeyond clinical performance, cancer screening strategies must be economically viable. I employ microsimulation modeling and decision-analytic approaches to project long-term outcomes, cost-effectiveness, and resource implications of various screening strategies. These studies provide robust evidence for healthcare decision-making and policy formulation in cancer prevention and early detection.\n\n\n\n\n\n5. AI & Large Language Models\nAI-driven imaging, NLP, and protocol evaluation.\nThe rapid progress of artificial intelligence (AI) and large language models (LLMs) offers unprecedented opportunities for cancer screening and clinical research. I explore AI-driven imaging, natural language processing, and decision-support systems to improve colorectal cancer risk stratification and screening management.\n\n\n\n\n\n6. Methodology & Quality Control\nImproving rigor in clinical research.\nHigh-quality clinical research is fundamental to evidence-based medicine, yet many studies face challenges in design, implementation, and reporting. I lead the development of methodological evaluation frameworks and intelligent support systems for clinical research, enabling comprehensive quality control across the research lifecycle. These initiatives improve scientific rigor and reproducibility, contributing to the advancement of clinical research quality in China and globally. In parallel, I investigate the use of LLMs for automated evaluation of clinical trial protocols, aiming to enhance the quality and efficiency of cancer research."
  },
  {
    "objectID": "members.html",
    "href": "members.html",
    "title": "Group Members",
    "section": "",
    "text": "Principal Investigator\n\n\n\n\n\nResearchers\n\n\n\n\n\nPhD Candidates\n\n\n\n\n\nMaster Students\n\n\n\n\n\nAlumni"
  },
  {
    "objectID": "Running Projects.html",
    "href": "Running Projects.html",
    "title": "Running Projects",
    "section": "",
    "text": "Our group is currently conducting several interdisciplinary projects focusing on precision prevention, early detection, and clinical research methodology.\nThese projects integrate genomics, microbiome, AI/LLMs, and health policy modeling, aiming to transform colorectal cancer screening and prevention strategies in China and globally.\n\n\n\nRisk-adapted Screening for Colorectal Cancer\nWe conducted the first large-scale randomized controlled trial (RCT) in China to compare the feasibility, participation, and diagnostic yield of risk-adapted colorectal cancer (CRC) screening with colonoscopy and fecal immunochemical test (FIT) ‚Äî the TARGET-C trial. Approximately 20,000 participants aged 50‚Äì74 years were enrolled. The trial has built a comprehensive database and biobank, forming a robust platform for future CRC prevention and early detection research.\n\n\nPolygenic Risk Score for Colorectal Cancer\nWe are developing and validating polygenic risk score (PRS) models by integrating data from the China Kadoorie Biobank and multiple population-based screening cohorts. This project aims to provide precise estimation of individual absolute risk and enable large-scale, genetics-informed risk-adapted screening.\n\n\nGut Microbiome and CRC\nWe investigate gut microbial signatures and host‚Äìmicrobiome interactions influencing CRC development. Integrating metagenomic, lifestyle, and genetic data, we build metagenomic risk scores (MRS) for early detection, and study how environmental and genetic factors shape the microbiome and carcinogenesis.\n\n\nAI and Large Language Models for Cancer Prevention\nDeveloping AI- and LLM-driven platforms for the end-to-end management of cancer screening ‚Äî from intelligent risk assessment to personalized follow-up. A pilot study, INTEL-PATH CRC, is evaluating the feasibility of AI-assisted screening strategies in real-world settings.\n\n\nHealth Economics & Policy Simulation\nApplying microsimulation and decision-analytic models to evaluate the long-term effectiveness and cost-effectiveness of both primary (risk factor control) and secondary (screening-based) prevention strategies for CRC. These analyses guide evidence-based policy and optimize prevention resources.\n\n\nLifestyle and Cancer Comorbidity\nInvestigating how lifestyle factors (diet, physical activity, smoking, alcohol, metabolic status) influence comorbidity patterns between cancer and chronic diseases. The project identifies modifiable risks and promotes integrated prevention and survivorship care.\n\n\nNovel plasma proteomics-based colorectal cancer screening biomarker\nUsing mass spectrometry‚Äìbased plasma proteomics to discover and validate circulating protein biomarkers for early colorectal cancer detection. By integrating proteomic, genetic, and clinical data, this project enhances non-invasive colorectal cancer screening and early-detection tools.\n\n\nCREDIT: Clinical Research Intelligent Design & Evaluation Tool\nCREDIT is an AI-empowered platform for clinical research design, evaluation, and quality management. Leveraging large language models and knowledge-graph reasoning, it assesses study rigor and provides automated feedback aligned with international standards (CONSORT, STROBE, PRISMA).\n\n\nIntegrated Screening for Upper Gastrointestinal and Colorectal Cancer\nDeveloping a combined screening strategy for upper GI and colorectal cancers in high-altitude Tibetan populations, integrating endoscopic and non-invasive methods to improve efficiency and explore shared etiological pathways.\n\n\nGlobal Lifetime Risk and Preventable Burden of Colorectal Cancer\nQuantifying the global lifetime risk and preventable incidence of colorectal cancer attributable to modifiable risk factors across countries worldwide. This study will use comparative modeling and population-attributable risk estimation to assess regional variations and identify the potential impact of targeted prevention strategies, providing evidence to guide international cancer prevention and screening policies.\n\n\nCervical cancer screening and triaging strategy\nFor women at high risk of cervical cancer, this study will evaluate the effectiveness of E6/E7 mRNA testing, DNA methylation markers, dual-stain cytology (p16/Ki-67), and conventional cytology in triaging hrHPV-positive cases. We aim to compare their diagnostic performance and explore the optimal triaging strategy that achieves a balance between accuracy, feasibility, and cost-effectiveness."
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications",
    "section": "",
    "text": "NoteLinks\n\n\n\n\n\nORCID: https://orcid.org/0000-0001-6171-1162\n\nPubMed: Search Publications"
  },
  {
    "objectID": "publications.html#full-academic-papers-published-in-english",
    "href": "publications.html#full-academic-papers-published-in-english",
    "title": "Publications",
    "section": "Full Academic Papers Published in English",
    "text": "Full Academic Papers Published in English"
  },
  {
    "objectID": "publications.html#2025",
    "href": "publications.html#2025",
    "title": "Publications",
    "section": "2025",
    "text": "2025\n\nleading author\n\n\nGuo L#, Wang L#, Cai L#, Zhang Y#, Feng X#, Zhu C, Gao W, Cardoso R, Yang H, Dai M, Brenner H, Chen H. Global Distribution of Colorectal Cancer Staging at Diagnosis: An Evidence Synthesis. Clin Gastroenterol Hepatol*. 2024 Dec 16:S1542-3565(24)01104-2. Link\nSun C, Zhang X, Su Z, Yao WH, Chen H, Zeng YP. Global, regional and national burdens of atopic dermatitis from 1990 to 2021: a trend analysis from the Global Burden of Disease Study 2021. J Am Acad Dermatol. 2025 Jun 19:S0190-9622(25)02369-2. Link\nHan J#, Zhang L#, Chen Y#, Zhang Y, Wang L, Cai R, Li M, Dai Y, Dang L, Chen H, Zhu L. Global HPV vaccination programs and coverage rates: a systematic review. EClinicalMedicine. 2025 Jun 9;84:103290.Link\nChen Y#, Zhang Y#, Yan Y#, Han J#, Zhang L, Cheng X, Lu B, Li N, Luo C, Zhou Y, Song K, Iwasaki M, Dai M, Wu D*, Chen H. Global colorectal cancer screening programs and coverage rate estimation: an evidence synthesis. J Transl Med. 2025 Jul 22;23(1):811.Link\nZhang Y#, Luo J#, Chen K, Li N, Luo C, Di S, Qin J, Zhang F, Chen H, Dai M. Cross-cohort analysis identifies shared gut microbial signatures and validates microbial risk scores for colorectal cancer. J Transl Med. 2025 Jun 17;23(1):676.Link\nZhou Y#, Li N#, Luo J#, Chen Y, Zhang Y, Dai M, Chen H. Participation and Yield in Multiple Rounds of Colorectal Cancer Screening based on Fecal Immunochemical Test: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2025;120(3):524-530.Link\nZhang Y#, Song K#, Zhou Y#, Chen Y, Cheng X, Dai M, Wu D, Chen H. Accuracy and long-term effectiveness of established screening modalities and strategies in colorectal cancer screening: an umbrella review. Int J Cancer*. 2025;157(1):126-138.Link\nLuo C#, Tian B#, Zhou Y, Luo J, Shang Q, Yu S, Dai M, Li Y*, **Chen H. Deciphering the Interplay Among Inflammatory Bowel Disease, Gut Microbiota, and Inflammatory Biomarkers in the Risk of Colorectal Cancer. Mediators Inflamm*. 2025 Mar 8:2025:4967641.Link\nSong K#, Luo J#, Zhang Y, Wu D, Chen H, Dai M. Gut microbiome mediates the associations between lifestyle factors and risk of colorectal high-risk adenoma: results from a population-based cohort study. mSystems. 2025 Sep 22:e0093325.Link\nSong K#, Zhang S#, Luo J, Lu B, Li J, Zhou Y, Chen Y, Zhang Y, Yang A, Chen H, Wu D. Risk of Metachronous Advanced Neoplasia After Colonoscopy in Patients With Different Index Findings. J Gastroenterol Hepatol. 2025 Aug;40(8):1942-1953.Link\nYan Y#, Luo C#, Chen Y, Cheng X, Luo J, Zhou Y, Li N, Zhang Y, Lu B, He Z, Song K, Wu D, Chen H, Dai M. Evaluation of a novel approach for colorectal cancer screening using an intelligent tool (INTEL-PATH CRC): a protocol for a multicentre, real-world, cohort study. BMJ Open. 2025 Jul 18;15(7):e098679. Link\n\n\ncontributting author\n\n\nLi N, Luo C, Chen Y, Cheng X, Luo J, Yan Y, Zhang Y, Lu B, He Z, Song K, Wu D, Tian J, Miao X, Chen H, Hu F, Dai M. Identification and validation of blood leukocyte DNA methylation biomarkers for early detection of colorectal neoplasm. Chin Med J (Engl). 2025 Jun 6. doi: 10.1097/CM9.0000000000003681. Epub ahead of print. PMID: 40474333Link\nCao M, Liufu R, Wang B, Pan W, Chen H, Su L, Long Y, Zhou X, Weng L, Du B; Critical Care Clinical Trials Group; China National Critical Care Quality Control Center Group. Population-wise incidence and outcomes of patients requiring invasive and non-invasive mechanical ventilation in China: a nationwide retrospective analysis by age, sex, and comorbidity. Ann Intensive Care. 2025 Aug 14;15(1):120.Link\nHuang S, Jia Y, Zhang Y, Chen H, Deng C, Fei Y. Effects of glucocorticoid withdrawal on relapse risk in systemic lupus erythematosus: A systematic review and meta-analysis. iScience. 2025 Jun 13;28(7):112875.Link\nYan X, Li X, Chen Y, Ouzhu M, Guo Z, Lyu C, Yang D, Chen H, Xie F, Wu D. Health economics evaluation of diagnostic strategies for gastro-oesophageal reflux disease with reflux symptoms in China: a modelling study. BMJ Open. 2025 May 14;15(5):e093108. Link\nLi N, Song K, Chen H, Dai M#. Advance and challenge of DNA methylation as cancer biomarkers for risk stratification, screening and early detection. J Natl Cancer Cent. 2025 Jan 30;5(2):108-112.Link\nLu Z, Chen C, Zhang H, Li B, Liu Y, Guo J, Xu R, Shi K, Ma Q, Zhang M, Cai Y, Huang J, Geng H, Fan L, Ning C, Li Y, Chen S, Tian W, Hu K, Li H, Yang X, Huang C, Wei Y, Zhu X, Li X, Xiong Z, Cai M, Wang X, Zhang S, Chen H, Dai M, Chen K, Jin M, Jin M, Zhu Y, Tian J, Miao X. Characterization of cis-regulatory elements and functional variants in colorectal cancer using epigenomics and CRISPRi screenings. Nat Cancer. 2025 Aug 25. doi: 10.1038/s43018-025-01031-z. Epub ahead of print. PMID: 40854986.Link"
  },
  {
    "objectID": "publications.html#2024",
    "href": "publications.html#2024",
    "title": "Publications",
    "section": "2024",
    "text": "2024\n\nleading author\n\n\nLu B, Luo J, Yan Y, Zhang Y, Luo C, Li N, Zhou Y, Wu D, Dai M, Chen H. Evaluation of long-term benefits and cost-effectiveness of nation-wide colorectal cancer screening strategies in China in 2020‚Äì2060: a modelling analysis. Lancet Reg Health West Pac*. 2024;51:101172.Link\nLu B#, Xu Y#, Li N, Zhou Y, Ma X, Chen Y, Dong R, Zhou X, Dai M, Chen H, Weng L, Du B. Overall and geographic pattern of incidence, case fatality and mortality of sepsis among hospitalised non-child cancer patients in China: a national observational study. Sci Bull (Beijing). 2024 Jun 15;69(11):1637-1641.Link\nDai Y#, Chen H#, Yu J, Cai J, Lu B, Dai M, Zhu L. Global and regional trends in the incidence and prevalence of uterine fibroids and attributable risk factors at the national level from 2010 to 2019: A worldwide database study. Chin Med J (Engl)*. 2024 Nov 5;137(21):2583-2589. Link\nCai J#, Lu B#, Chen H#, Lu M, Zhang Y, Luo C, You L, Dai M, Zhao Y. The impacts of exposure to risk factors during youth on the increasing global trend of early-onset pancreatic cancer. Public Health. 2024 Apr;229:65-72. Link\nZhou Y#, Song K#, Chen Y, Zhang Y, Dai M, Wu D, Chen H. Burden of six major types of digestive system cancers globally and in China. Chin Med J (Engl). 2024 Aug 20;137(16):1957-1964. Link\nLuo C, Luo J, Zhang Y, Lu B, Li N, Zhou Y, Chen S, Wu S, Zhang Q, Dai M, Chen H. Associations between blood glucose and early- and late-onset colorectal cancer: evidence from two prospective cohorts and Mendelian randomization analyses. J Natl Cancer Cent. 2024;4(3):241-248.Link\nSong K, He W, Wu Z, Meng J, Tian W, Zheng S, Mu D, Wang R, Chen H, Zhu Y, Wu D. Early clinical predictors of infected pancreatic necrosis: a multicentre cohort study. eGastroenterology. 2024;2:e100095. Link\nChen H#, Lu B#, Xu Y#, Li N, Zhou Y, Ma X, Chen Y, Dong R, Zhou X, Dai M, Weng L, Du B. Trend in sepsis burden among hospitalized non-child cancer patients in China, 2017‚Äì2019: a nationwide cross-sectional study. Med Plus. 2024;1(4):100062.Link\nChen H, Dai M#. Reply. Clin Gastroenterol Hepatol. 2024 Feb;22(2):433.Link\nYang Z, Zhou Y, Han Z, He K, Zhang Y, Wu D, Chen H. The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta-analyses. Sci Rep.¬†2024 May 2;14(1):10069.Link\n\n\ncontributting author\n\n\nGuo L, Zhu C, Cai L, Zhang X, Fang Y, Chen H, Yang H. Global burden of lung cancer in 2022 and projected burden in 2050. Chin Med J (Engl). 2024 Nov 5;137(21):2577-2582.Link\nWang M, Chen H, Wong MCS, Huang J, Jin Y, Zheng ZJ. Effects of screening coverage and screening quality assurance on cervical cancer mortality: Implication for integrated framework to monitor global implementation of cervical cancer screening programmes. J Glob Health. 2024 Oct 25;14:04189.Link"
  },
  {
    "objectID": "publications.html#2022-2023",
    "href": "publications.html#2022-2023",
    "title": "Publications",
    "section": "2022-2023",
    "text": "2022-2023\n\nleading author\n\n\nChen H#, Shi J#, Lu M, Li Y, Du L, Liao X, Wei D, Dong D, Gao Y, Zhu C, Ying R, Zheng W, Yan S, Xiao H, Zhang J, Kong Y, Li F, Zou S, Liu C, Wang H, Zhang Y, Lu B, Luo C, Cai J, Tian J, Miao X, Ding K, Brenner H, Dai M. Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C). Clin Gastroenterol Hepatol. 2023;21(3):808-818.Link\nZhang Y, Chen H, Lu M, Cai J, Lu B, Luo C, Dai M. Habitual Diet Pattern Associations with Gut Microbiome Diversity and Composition: Results from a Chinese Adult Cohort. Nutrients. 2022;14(13):2639.Link\nChen H, Lu B, Dai M. Colorectal Cancer Screening in China: Status, Challenges, and Prospects - China, 2022. China CDC Wkly. 2022;4(15):322-328.Link\nLu B, Wang L, Lu M, Zhang Y, Cai J, Luo C, Chen H, Dai M. Microsimulation Model for Prevention and Intervention of Coloretal Cancer in China (MIMIC-CRC): Development, calibration, validation, and application. Front Oncol. 2022;12:883401.Link\nLuo C#, Wang L#, Zhang Y, Lu M, Lu B, Cai J, Chen H, Dai M. Advances in breast cancer screening modalities and status of global screening programs. Chronic Dis Transl Med. 2022;1-12.Link\nWang L, Chen H#, Zhu Y, Lu M, Wang Y, Chen X, Ma W, Du L, Chen W. One-sample quantitative and two-sample qualitative faecal immunochemical tests for colorectal cancer screening: a cross-sectional study in China. BMJ Open. 2022;12(5):e059754.Link\nLu M, Zhang Y, Cai J, Lu B, Luo C, Chen H, Dai M. Head-to-head comparison of a risk-adapted screening strategy using various risk prediction models in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2022;37(7):1244-1252.Link\nCai J, Chen H#, Lu M, Zhang Y, Lu B, Luo C, Feng X, You L, Dai M, Zhao Y. Association between Temporal Glycemic Change and Risk of Pancreatic Cancer in Men: A Prospective Cohort Study. Cancers (Basel). 2022 Jul 13;14(14):3403.Link\nLuo C, Li N, Lu B, Cai J, Lu M, Zhang Y, Chen H, Dai M. Global and regional trends in incidence and mortality of female breast cancer and associated factors at national level in 2000 to 2019. Chin Med J (Engl). 2022;135(1):42-51.Link\n\n\ncontributting author\n\n\nSong S, Pei L, Chen H, Zhang Y, Sun C, Yi J, Huang Y. Analysis of hospital and payer costs of care: aggressive warming versus routine warming in abdominal major surgery. Front Public Health. 2023 Nov 2;11:1256254.Link\nChen C, Cai Y, Liu Y, Chen S, Li Y, Zhang F, Zhang M, Lu Z, Ying P, Huang J, Fan L, Cai X, Ning C, Wang W, Jiang Y, Zhang H, Yang S, Wang Z, Wang X, Zhang S, Huang C, Xu B, Fu Z, Song Q, Jin M, Chen K, Chen H, Dai M, Miao X, Yang X, Zhu Y, Tian J. Pan-Cancer Analysis of Microbiome Quantitative Trait Loci. Cancer Res. 2022 Oct 4;82(19):3449-3456.Link\nWu Z, Tan F, Yang Z, Wang F, Cao W, Qin C, Dong X, Zheng Y, Luo Z, Zhao L, Yu Y, Xu Y, Ren J, Shi J, Chen H, Li J, Tang W, Shen S, Wu N, Chen W, Li N, He J. Sex disparity of lung cancer risk in non-smokers: a multicenter population-based prospective study based on China National Lung Cancer Screening Program. Chin Med J (Engl). 2022 Jun 5;135(11):1331-1339.Link\nWu Z, Xie S, Wang F, Chen S, Su K, Li F, Cui H, Cao W, Yu Y, Qin C, Zheng Y, Dong X, Yang Z, Luo Z, Zhao L, Xu Y, Chen H, Li J, Wang G, Wu S, Dai M, Li N, He J. BMI changes and the risk of lung cancer in male never-smokers: A prospective cohort study. Cancer Med. 2022 Mar;11(5):1336-1346.Link"
  },
  {
    "objectID": "publications.html#2020-2021",
    "href": "publications.html#2020-2021",
    "title": "Publications",
    "section": "2020-2021",
    "text": "2020-2021\n\nleading author\n\n\nLi N#, Lu B#, Luo C, Cai J, Lu M, Zhang Y, Chen H, Dai M. Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America. Cancer Lett. 2021;522:255-268. Link\nCai J#, Chen H#, Lu M, Zhang Y, Lu B, You L, Zhang T, Dai M, Zhao Y. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett. 2021;520:1-11. Link\n\nChen H#, Liu L#, Lu M, Zhang Y, Lu B, Zhu Y, Tian J, Li X, Nie S, Miao X, Dai M. Implications of Lifestyle Factors and Polygenic Risk Score for Absolute Risk Prediction of Colorectal Neoplasm and Risk-Adapted Screening. Front Mol Biosci. 2021;8:685410.Link\nChen H#, Wang L, Lu M, Zhu C, Zhu Y, Ma W, Chen X, Du L, Chen W. Comparative yield and efficiency of strategies based on risk assessment and fecal immunochemical test in colorectal cancer screening: A cross-sectional population-based analysis. Chin J Cancer Res. 2021;33(4):512-521. Link\nZhang Y, Lu M, Lu B, Liu C, Ma Y, Liu L, Miao X, Qin J, Chen H, Dai M. Leveraging Fecal Microbial Markers to Improve the Diagnostic Accuracy of the Fecal Immunochemical Test for Advanced Colorectal Adenoma. Clin Transl Gastroenterol. 2021;12(8):e00389.Link\nLu M, Wang L, Zhang Y, Liu C, Lu B, Du L, Liao X, Dong D, Wei D, Gao Y, Shi J, Ren J, Chen H, Dai M. Optimizing Positivity Thresholds for a Risk-Adapted Screening Strategy in Colorectal Cancer Screening. Clin Transl Gastroenterol. 2021;12(8):e00398.Link\nLu M, Zhang YH, Lu B, Cai J, Liu CC, Chen H, Dai M. Head-to-head comparison of the test performance of self-administered qualitative vs.¬†laboratory-based quantitative fecal immunochemical tests in detecting colorectal neoplasm. Chin Med J (Engl). 2021;134(11):1335-1344. Link\nLu B#, Li N#, Luo CY, Cai J, Lu M, Zhang YH, Chen H, Dai M. Colorectal cancer incidence and mortality: the current status, temporal trends and their attributable risk factors in 60 countries in 2000-2019. Chin Med J (Engl). 2021;134(16):1941-1951. Link\nChen H, Lu M, Zhang YH, Dai M. Divergent detection rates of fecal immunochemical test and questionnaire-based risk assessment for detecting proximal and distal advanced colorectal adenomas. Chin Med J (Engl)*. 2021;134(5):605-607.Link\nChen H, Lu M, Liu C, Zou S, Du L, Liao X, Dong D, Wei D, Gao Y, Zhu C, Zhu L, Zheng W, Xiao H, Kong Y, Yin H, Zhou H, Ying R, Wang B, Zhang J, Zhang X, Zhang Q, Zhang X, Zhang Y, Wang H, Guo L, Liu L, Ren J, Shi J, Li N, Miao X, Brenner H, Dai M. Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET-C). Am J Gastroenterol. 2020;115(8):1264-1274. Link\nWang H, Zhang B, Li X, Zhou D, Li Y, Jia S, Qi S, Xu A, Zhao X, Wang J, Bai Z, Cao B, Li N, Dai M, Chen H, Huang J. Identification and Validation of Novel Serum Autoantibody Biomarkers for Early Detection of Colorectal Cancer and Advanced Adenoma. Front Oncol. 2020;10:1081.Link\n\n\ncontributting author\n\n\nWang H, Zhu Y, Chen H, Yang N, Wang X, Li B, Ying P, He H, Cai Y, Zhang M, Niu S, Li Y, Lu Z, Peng X, Zou D, Zhong R, Chang J, Dai M, Tian J, Miao X. Colorectal cancer risk variant rs7017386 modulates two oncogenic lncRNAs expression via ATF1-mediated long-range chromatin loop. Cancer Lett. 2021 Oct 10;518:140-151.Link\nCao M, Li H, Sun D, He S, Yu Y, Li J, Chen H, Shi J, Ren J, Li N, Chen W. Cancer screening in China: The current status, challenges, and suggestions. Cancer Lett. 2021 May 28;506:120-127. Link\nLi J, Hu P, Shi J, Fan Y, Ren J, Chen H, Li N, Liao X, Liu Y, Du L, Wu N, Tang W, Zhang Y, Zou S, Pinsky P, Prorok P, Fagerstrom R, Taylor M, Kramer B, Dai M, He J; China Cancer Screening Trial Feasibility Study Group. Results of the cancer screening feasibility study in China: a multicentered randomized controlled trial of lung and colorectal cancer screening. J Natl Cancer Cent. 2021 Jul 31;1(4):132-138. Link\nSong S, Duan Y, Huang J, Wong MCS, Chen H, Trisolini MG, Labresh KA, Smith SC Jr, Jin Y, Zheng ZJ. Socioeconomic Inequalities in Premature Cancer Mortality Among U.S. Counties During 1999 to 2018. Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1375-1386.Link\nFeng X, Wang G, Lyu Z, Chen S, Wei L, Li X, Wen Y, Chen Y, Xie S, Cui H, Chen H Li J, Lin C, Ren J, Shi J, Wu S, Dai M, Li N, He J. The association between fasting blood glucose trajectory and cancer risk in Chinese population without diabetes. Int J Cancer. 2020 Aug 15;147(4):958-966.Link\nLyu Z, Li N, Chen S, Wang G, Tan F, Feng X, Li X, Wen Y, Yang Z, Wang Y, Li J, Chen H, Lin C, Ren J, Shi J, Wu S, Dai M, He J. Risk prediction model for lung cancer incorporating metabolic markers: Development and internal validation in a Chinese population. Cancer Med. 2020 Jun;9(11):3983-3994.Link\nGuo L, Chen H, Wang G, Lyu Z, Feng X, Wei L, Li X, Wen Y, Lu M, Chen Y, Shi J, Ren J, Lin C, Yu X, Chen S, Wu S, Li N, Dai M, He J. Development of a risk score for colorectal cancer in Chinese males: A prospective cohort study. Cancer Med. 2020 Jan;9(2):816-823.Link"
  },
  {
    "objectID": "publications.html#2018-2019",
    "href": "publications.html#2018-2019",
    "title": "Publications",
    "section": "2018-2019",
    "text": "2018-2019\n\nleading author\n\n\nChen H#, Li N#, Ren J, Feng X, Lyu Z, Wei L, Li X, Guo L, Zheng Z, Zou S, Zhang Y, Li J, Zhang K, Chen W, Dai M, He J. Participation and yield of a population-based colorectal cancer screening programme in China. Gut. 2019;68(8):1450-1457.Link\n\nWang Y#, Chen H#, Li N, Ren J, Zhang K, Dai M, He J. Ultrasound for Breast Cancer Screening in High-Risk Women: Results From a Population-Based Cancer Screening Program in China. Front Oncol. 2019;9:286. Link\nLu M, Luo X, Li N, Chen H, Dai M. Diagnostic Accuracy of Fecal Occult Blood Tests For Detecting Proximal Versus Distal Colorectal Neoplasia: A Systematic Review And Meta-Analysis. Clin Epidemiol. 2019;11:943-954.Link\n\nChen H#, Li N#, Shi J, Ren J, Liu C, Zhang Y, Jiang Z, Zhang Z, Dai M. Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial. BMJ Open. 2019;9(4):e025935.Link\nChen H#, Zhang Y#, Li S, Li N, Chen Y, Zhang B, Qu C, Ding H, Huang J, Dai M. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manag Res. 2018 Jul 10;10:1947-1958.Link\n\nLi S, Li X, Xu A, Zhang B, He X, Chen H, Huang J. Screening and clinical evaluation of dominant peptides of centromere protein F antigen for early diagnosis of hepatocellular carcinoma. Mol Med Rep. 2018 Mar;17(3):4720-4728.Link\n\n\ncontributting author\n\n\nTang W, Peng Q, Lyu Y, Feng X, Li X, Wei L, Li N, Chen H, Chen W, Dai M, Wu N, Li J, Huang Y. Risk prediction models for lung cancer: Perspectives and dissemination. Chin J Cancer Res. 2019 Apr;31(2):316-328.Link\nLyu Z, Li N, Wang G, Feng X, Chen S, Su K, Li F, Wei L, Li X, Xie S, Guo L, Chen Y, Tan F, Yin J, Cui H, Chen H, Li J, Ren J, Shi J, Wu S, Dai M, He J. Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study. Int J Cancer. 2019 Jun 15;144(12):2972-2984.Link\nLi X, Chen H, Wang G, Feng X, Lyu Z, Wei L, Wen Y, Chen S, Wu S, Hang D, Dai M, Li N, He J. Metabolic Syndrome Components and the Risk of Colorectal Cancer: A Population-Based Prospective Study in Chinese Men. Front Oncol. 2019 Oct 17;9:1047.Link\nGuo L, Chen H, Wang G, Lyu Z, Feng X, Wei L, Li X, Wen Y, Lu M, Chen Y, Shi J, Ren J, Lin C, Yu X, Chen S, Wu S, Li N, Dai M, He J. Development of a risk score for colorectal cancer in Chinese males: A prospective cohort study. Cancer Med. 2020 Jan;9(2):816-823.Link\nWei L, Li N, Wang G, Feng X, Lyu Z, Li X, Wen Y, Chen Y, Chen H, Chen S, Wu S, Dai M, He J. Waist Circumference Might Be a Predictor of Primary Liver Cancer: A Population-Based Cohort Study. Front Oncol. 2018 Dec 12;8:607.Link"
  },
  {
    "objectID": "publications.html#2014-2017",
    "href": "publications.html#2014-2017",
    "title": "Publications",
    "section": "2014-2017",
    "text": "2014-2017\n\nleading author\n\n\nChen H, Werner S, Brenner H. Fresh vs Frozen Samples and Ambient Temperature Have Little Effect on Detection of Colorectal Cancer or Adenomas by a Fecal Immunochemical Test in a Colorectal Cancer Screening Cohort in Germany. Clin Gastroenterol Hepatol. 2017;15(10):1547-1556.e5.Link\n\nChen H, Qian J, Werner S, Cuk K, Knebel P, Brenner H. Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer. Clin Epidemiol*. 2017;9:517-526.Link\nChen H, Knebel P, Brenner H. Empirical evaluation demonstrated importance of validating biomarkers for early detection of cancer in screening settings to limit the number of false-positive findings. J Clin Epidemiol. 2016;75:108-14.Link\nChen H, Zucknick M, Werner S, Knebel P, Brenner H. Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting. Clin Cancer Res. 2015;21(14):3318-26.Link\nChen H, Chen XZ, Waterboer T, Castro FA, Brenner H. Viral infections and colorectal cancer: a systematic review of epidemiological studies. Int J Cancer. 2015;137(1):12-24.Link\nChen H, Werner S, Tao S, Z√∂rnig I, Brenner H. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer. Cancer Lett. 2014;346(2):178-87.Link\nPeng C, Chen H#, Wallwiener M, Modugno C, Cuk K, Madhavan D, Trumpp A, Heil J, Marm√© F, Nees J, Riethdorf S, Schott S, Sohn C, Pantel K, Schneeweiss A, Yang R, Burwinkel B. Plasma S100P level as a novel prognostic marker of metastatic breast cancer. Breast Cancer Res Treat. 2016 Jun;157(2):329-338.Link\n\n\ncontributting author\n\n\nFeng X, Wang G, Li N, Lyu Z, Chen S, Wei L, Chen Y, Xie S, Yang W, Yin J, Cui H, Chen H, Ren J, Shi J, Wu S, Dai M, He J. The association between fasting blood glucose and the risk of primary liver cancer in Chinese males: a population-based prospective study. Br J Cancer. 2017 Oct 24;117(9):1405-1411.Link\nBrenner H, Niedermaier T, Chen H. Strong subsite-specific variation in detecting advanced adenomas by fecal immunochemical testing for hemoglobin. Int J Cancer. 2017 May 1;140(9):2015-2022.Link\nBrenner H, Chen H. Fecal occult blood versus DNA testing: indirect comparison in a colorectal cancer screening population. Clin Epidemiol. 2017 Jul 13;9:377-384.Link\nWerner S, Krause F, Rolny V, Strobl M, Morgenstern D, Datz C, Chen H, Brenner H. Evaluation of a 5-Marker Blood Test for Colorectal Cancer Early Detection in a Colorectal Cancer Screening Setting. Clin Cancer Res. 2016 Apr 1;22(7):1725-33.Link\nWerner S, Chen H, Butt J, Michel A, Knebel P, Holleczek B, Z√∂rnig I, Eichm√ºller SB, J√§ger D, Pawlita M, Waterboer T, Brenner H. Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. Sci Rep.¬†2016 May 3;6:25467.Link\nWerner S, Chen H, Tao S, Brenner H. Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer. 2015 May 15;136(10):2243-52.Link\nChen XZ, Chen H, Castro FA, Hu JK, Brenner H. Epstein-Barr virus infection and gastric cancer: a systematic review. Medicine (Baltimore). 2015 May;94(20):e792.Link"
  },
  {
    "objectID": "publications.html#guideline-and-standard",
    "href": "publications.html#guideline-and-standard",
    "title": "Publications",
    "section": "Guideline and Standard",
    "text": "Guideline and Standard\n\n„ÄäÂä≥Âä®ËÄÖÁôåÁóáÁ≠õÊü•ÊúçÂä°ËßÑËåÉ„ÄãÔºàT/CHAA 023-2023Ôºå‰∏≠ÂõΩÂÅ•Â∫∑ÁÆ°ÁêÜÂçè‰ºöÔºâ‚Äî‚ÄîËµ∑Ëçâ‰∏ìÂÆ∂\nSpecification for Cancer Screening Services for Workers (T/CHAA 023-2023, Chinese Health Management Association) ‚Äî Drafting Expert\n„ÄäÁªìÁõ¥ËÇ†ÁôåÂâçÁóÖÂèòÊ≤ªÊú™ÁóÖÂπ≤È¢ÑÊåáÂçó„ÄãÔºàT/CACM 1473-2023Ôºå‰∏≠Âçé‰∏≠ÂåªËçØÂ≠¶‰ºöÔºâ‚Äî‚ÄîËµ∑Ëçâ‰∏ìÂÆ∂\nGuideline on Preventive Interventions for Colorectal Precancerous Lesions (T/CACM 1473-2023, China Association of Chinese Medicine) ‚Äî Drafting Expert\n„Ää‰∏≠ÂõΩÁªìÁõ¥ËÇ†ÁôåÁ≠õÊü•‰∏éÊó©ËØäÊó©Ê≤ªÊåáÂçó„ÄãÔºà2020ÔºåÂåó‰∫¨Ôºâ‚Äî‚ÄîËµ∑Ëçâ‰∏ìÂÆ∂\nChina Guideline for Colorectal Cancer Screening and Early Detection and Treatment (2020, Beijing) ‚Äî Drafting Expert\nMonographs and Books\n„ÄäÁªìÁõ¥ËÇ†ÁôåÁ≠õÊü•„Äã ËæΩÂÆÅÁßëÂ≠¶ÊäÄÊúØÂá∫ÁâàÁ§æÔºå2024Âπ¥12Êúà ‚Äî‚Äî ÁºñÂßî\nColorectal Cancer Screening, Liaoning Science and Technology Press, December 2024 ‚Äî Editorial Board Member\n„ÄäÂÆûÁî®Âç´ÁîüÁªüËÆ°Â≠¶„Äã Âåó‰∫¨Â§ßÂ≠¶ÂåªÂ≠¶Âá∫ÁâàÁ§æÔºå2023Âπ¥9Êúà ‚Äî‚Äî ÁºñÂßî\nPractical Health Statistics, Peking University Medical Press, September 2023 ‚Äî Editorial Board Member\n„ÄäÊµÅË°åÁóÖÂ≠¶„Äã ÂõΩÂÆ∂ÂºÄÊîæÂ§ßÂ≠¶Âá∫ÁâàÁ§æÔºå2022Âπ¥7Êúà ‚Äî‚Äî ÁºñÂßî\nEpidemiology, National Open University Press, July 2022 ‚Äî Editorial Board Member\n„ÄäÂåªÁîüÂñä‰Ω†Êù•‰ΩìÊ£Ä„Äã ‰∏≠ÂõΩ‰∫∫Âè£Âá∫ÁâàÁ§æÔºå2022Âπ¥5Êúà ‚Äî‚Äî ÁºñÂßî\nDoctors Call You for Health Check-up, China Population Publishing House, May 2022 ‚Äî Editorial Board Member\n„Ää‰∏≠ÂõΩ‰∫∫Áæ§ÁôåÁóáÁ≠õÊü•Â∑•‰ΩúÊåáÂØºÊâãÂÜå„Äã ‰∫∫Ê∞ëÂç´ÁîüÂá∫ÁâàÁ§æÔºå2021Âπ¥10Êúà ‚Äî‚Äî ÁºñÂßî\nGuideline Manual for Cancer Screening in the Chinese Population, People‚Äôs Medical Publishing House, October 2021 ‚Äî Editorial Board Member\n„ÄäÁôåÁóáÈ¢ÑÈò≤‰∏éÁ≠õÊü•ÊåáÂçóÔºàÁßëÊôÆÁâàÔºâ„Äã ‰∫∫Ê∞ëÂç´ÁîüÂá∫ÁâàÁ§æÔºå2020Âπ¥10Êúà ‚Äî‚Äî ÁºñÂßî\nGuidelines for Cancer Prevention and Screening (Popular Science Edition), People‚Äôs Medical Publishing House, October 2020 ‚Äî Editorial Board Member"
  }
]